Original research at Richter
The area of our original research is a wide range of neuropsychiatric and neurodegenerative diseases, in which we aim to treat negative, cognitive and positive symptoms related to these disorders. Selecting biological targets associated with diseases is always a major challenge for our researchers, as it is of paramount importance for our future success. Selecting the ideal compound to act on requires dedicated work from our medicinal chemists, biologists, and pharmacologists over a period of 3-5 years. To achieve this goal, we use state-of-the-art technical tools, such as our automated test systems and chemistry software supported by artificial intelligence. If this new compound, which has successfully passed several safety studies, meets all the requirements, it is ready to be used in clinical trials. However, this research phase is not only long but also very costly, so most studies require the involvement of capital-intensive partners.